The C1INH was tested in ischemia-reperfusion mediated injuries, while Eculizumab was tested in other inflammatory diseases and was proposed for treatment of rheumatic diseases such as RA or systemic lupus erythematosus (SLE) [237,238,239]. Here, SERPING1 is linked to systemic lupus erythematosus.